Alan Harben, PhD
Pain Medicine · Roswell, GANPI 1669652095
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations.
Across 251 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neurocrine Biosciences, Inc.$691
- Teva Pharmaceuticals USA, Inc.$688
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$553
- Otsuka America Pharmaceutical, Inc.$547
- Lundbeck LLC$238
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,01699%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $1,452 |
| Neurocrine Biosciences, Inc. | 21 | $691 |
| Teva Pharmaceuticals USA, Inc. | 32 | $688 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $553 |
| Otsuka America Pharmaceutical, Inc. | 17 | $547 |
| Lundbeck LLC | 12 | $238 |
| Pfizer | 11 | $224 |
| Avanir Pharmaceuticals, Inc. | 9 | $189 |
| Axsome Therapeutics, Inc. | 6 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $147 |
| Averitas Pharma Inc. | 4 | $126 |
| MDD US Operations, LLC | 4 | $112 |
| Eisai Inc. | 2 | $107 |
| Currax Pharmaceuticals LLC | 6 | $101 |
| Merz North America, Inc. | 4 | $90 |
| Arbor Pharmaceuticals, Inc. | 4 | $76 |
| Merck | 3 | $62 |
| Dynasplint Systems Inc. | 1 | $52 |
| Biohaven Pharmaceuticals, Inc. | 2 | $46 |
| IBSA Pharma Inc. | 2 | $45 |
| Amgen | 2 | $44 |
| Merz Pharmaceuticals, LLC | 2 | $41 |
| Novartis | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Tersera Therapeutics LLC | 1 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| SPR Therapeutics, Inc | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Saol Therapeutics Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Microtransponder, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $12 |
| Ipsen Biopharmaceuticals, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,063 in reported general payments places this provider in the 70th percentile of 203 pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $157,001 |
| OxycontinOxycodone Hcl | 36 | $46,660 |
| BotoxOnabotulinumtoxina | 21 | $46,370 |
| NucyntaTapentadol Hcl | 14 | $35,877 |
| GenotropinSomatropin | 12 | $27,809 |
| Xtampza ErOxycodone Myristate | 21 | $16,819 |
| EliquisApixaban | 39 | $16,433 |
| OzempicSemaglutide | 11 | $11,022 |
| TradjentaLinagliptin | 30 | $6,802 |
| Fentanyl | 42 | $6,208 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,832 |
| JardianceEmpagliflozin | 14 | $4,529 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 150 | $4,347 |
| Gabapentin | 202 | $3,062 |
| Levetiracetam | 75 | $2,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $688 | $157,00113 claims |
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er | $20 | $52,69735 claims |
| AbbVieBotox | $1,452 | $46,37021 claims |
| PfizerGenotropin, Eliquis | $224 | $44,24251 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $147 | $4,83212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 203 pain medicine providers in Georgia.
Other pain medicine in Roswell
- Joseph KundukulamRoswell$10K
- Rutvij ShahColumbus$86K
- Siddardth UmapathyFort Eisenhower$41K
- Susheel DuaAtlanta$36K
- Subodh AgrawalAthens$34K
- Jose MathewLawrenceville$27K
- Zhuo SunAugusta$26K
- Maged HamzaGainesville$24K
- Ankur PatelGainesville$21K
- Margaret RisoGainesville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.